Is adidas' (XTRA:ADS) Push into Safety and Specialty Footwear Redefining Its Brand Ambitions?

• Adidas has launched a limited-edition PG x Adidas Adizero Impact Shades Cleat in partnership with Perfect Game, selling out at the WWBA World Championship and rolling out through additional Perfect Game storefronts in Florida and Alabama, while also revealing a new alliance with GLO, a Bunzl plc business, to develop a line of safety footwear for industries like construction and logistics, expected to debut in the second quarter of 2026.
• This dual push into specialty athletic footwear and workwear highlights Adidas's efforts to broaden its product portfolio and connect with new consumer segments beyond traditional sportswear.
• We'll explore how Adidas's collaboration-driven product launches and entry into the safety footwear category could shape its longer-term growth outlook.

Find companies with promising cash flow potential yet trading below their fair value.

adidas Investment Narrative Recap

To be a shareholder in adidas, you need confidence that its innovations and brand collaborations across sports and workwear can unlock new growth streams, helping offset competitive pressures, though recent launches like the Perfect Game cleat and industrial safety footwear are unlikely to move the needle on the main near-term challenge: containing margin risks from rising U.S. import tariffs and heightened price competition. For now, short-term catalysts still hinge on adidas’ ability to drive momentum in established categories despite these cost headwinds.

The PG x adidas Adizero Impact Shades Cleats launch in collaboration with Perfect Game stands out, showing adidas’ focus on targeted product releases that build brand equity among younger athletes, which ties directly to the importance of ongoing innovation and differentiated offerings for supporting volume and margin growth amid market rivalry. But while such releases generate buzz and reinforce adidas’ performance reputation, the persistent challenge of import cost inflation remains central for those watching profit trends more closely.

By contrast, one key risk that investors should be alert to is the possibility of further tariff increases at a time when...

Read the full narrative on adidas (it's free!)

adidas' outlook forecasts €31.1 billion in revenue and €2.5 billion in earnings by 2028, driven by an annual revenue growth rate of 8.2%. This represents an increase in earnings of €1.3 billion from the current €1.2 billion.

Uncover how adidas' forecasts yield a €237.35 fair value, a 22% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members gave adidas fair value estimates ranging from €194.37 to €756.03 across 9 analyses. While views span wide, many still weigh rising U.S. import tariffs as a critical influence on future profitability, your outlook may shift after reviewing the full spectrum of these community perspectives.

Explore 9 other fair value estimates on adidas - why the stock might be worth just €194.37!

Build Your Own adidas Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your adidas research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free adidas research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate adidas' overall financial health at a glance.

Seeking Other Investments?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 36 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The end of cancer? These 28 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com